Inorganic polyphosphates enhances nucleus pulposus tissue formation in vitro

J Orthop Res. 2017 Jan;35(1):41-50. doi: 10.1002/jor.23288. Epub 2016 May 30.

Abstract

Disc degeneration is associated with low back pain for which currently there is no optimal therapy so there is a great need to identify new treatment approaches. Inorganic polyphosphates (polyP) are linear polymers of orthophosphate units varying in chain length and present in many cell types. As polyP has anabolic effects on chondrocytes, we hypothesized that polyP treatment would enhance matrix accumulation by nucleus pulposus (NP) cells. NP cells isolated from bovine caudal discs were grown in 3D culture under normoxic or in select experiments under hypoxic conditions, in the presence or absence of various concentrations and sizes of polyP. Gene expression was determined using RT-PCR. Matrix accumulation was quantified by measuring proteoglycan and collagen contents. DAPI fluorescence shift was used to stain for polyP in tissue. DAPI staining showed polyP present predominantly in the pericellular region of in vitro formed tissue. PolyP treatment enhanced matrix accumulation in a concentration and chain length dependant manner. NP cells exposed to polyP-22 (22 phosphate units length) showed an increase in gene expression of aggrecan, Collagen II, Sox 9, and MMP-13 which was maintained for the 14 days of culture. This suggests that polyP may enhance NP tissue formation in vitro by upregulating the expression of matrix genes. As polyP enhances proteoglycan accumulation even under hypoxic conditions, this raises the possibility that polyP may be a novel treatment to induce NP regeneration. © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:41-50, 2017.

Keywords: bioactive compounds; inorganic polyphosphates; intervertebral disc degeneration; regeneration; tissue engineering; biological repair.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anabolic Agents / pharmacology
  • Anabolic Agents / therapeutic use*
  • Animals
  • Cattle
  • DNA / metabolism
  • Drug Evaluation, Preclinical
  • Extracellular Matrix / metabolism
  • Gene Expression / drug effects
  • Hypoxia / metabolism
  • Intervertebral Disc Degeneration / drug therapy*
  • Nucleus Pulposus / drug effects*
  • Nucleus Pulposus / metabolism
  • Polyphosphates / pharmacology
  • Polyphosphates / therapeutic use*
  • Primary Cell Culture

Substances

  • Anabolic Agents
  • Polyphosphates
  • DNA

Grants and funding